Company Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health.
The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body.
It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients.
The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018.
Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
| Country | United States |
| IPO Date | Jun 20, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 60 |
| CEO | Dr. Andrew Cheng M.D., Ph.D. |
Contact Details
Address: 601 Gateway Boulevard South San Francisco, California United States | |
| Website | https://www.akerotx.com |
Stock Details
| Ticker Symbol | AKRO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001744659 |
| CUSIP Number | 00973Y108 |
| ISIN Number | US00973Y1082 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andrew Cheng M.D., Ph.D. | President, Chief Executive Officer & Director |
| Dr. Jonathan M. Young J.D., Ph.D. | Co-Founder, Executive Vice President, Chief Operating Officer & Secretary |
| William R. White J.D. | Executive Vice President, Chief Financial Officer, Treasurer & Head of Corporate Development |
| Catriona Yale | Executive Vice President & Chief Development Officer |
| Dr. Timothy Rolph Ph.D. | Co-Founder & Chief Scientific Officer |
| John J. Schembri | Senior Vice President & Head of Finance |
| Patrick Lamy | Senior Vice President of Commercial Strategy |
| Scott A. Gangloff | Chief Technical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 30, 2024 | 4 | Filing |
| Dec 18, 2024 | 4 | Filing |
| Dec 18, 2024 | 4 | Filing |
| Dec 18, 2024 | 4 | Filing |
| Dec 18, 2024 | 4 | Filing |
| Dec 18, 2024 | 4 | Filing |
| Dec 18, 2024 | 4 | Filing |
| Dec 18, 2024 | 4 | Filing |
| Dec 12, 2024 | 4 | Filing |
| Dec 12, 2024 | 4 | Filing |